Jan 4, 2019
Richard Furie, MD, is chief, division of
rheumatology, at Northwell Health, and professor of medicine at
Hofstra/Northwell School of Medicine. Join us in this ACR
interview, as we discuss the story of interferon, lupus
therapeutics — including B cell depletion — and the future of lupus
research and treatments.
- Background on Dr. Furie :16
- The interview :56
- What advancements in the pathophysiology of lupus are you most
excited about? 1:10
- The interferon story 1:23
- The interferon story is not finished yet
- Dendritic cells in lupus patients
- What is “interferon signature?”
- Do we see different clinical phenotype in patients with high
interferon signature? 9:38
- What’s your opinion on the role of B cells?
- Any other pathophysiology mechanisms being used to target B
- Are we stretched thin in terms of number of lupus patients in
- How would designating lupus as an orphan disease change the way
it’s investigated? 16:40
- What is your main concern regarding study design?
- Looking 10 years ahead, do you think what we call “lupus” will
still be referred to as such, or will it be decompartmentalized
into different diseases? 21:26
- What’s the expense of cytokine profiling?
- What excites you the most about the future of lupus research?
- Thank you, Dr. Furie 24:41
- Recap 24:43
- Shout out to the 7th Annual Basic and Clinical Immunology for
the Busy Clinician: What is New and Hot in Immunology bootcamp in
Scottsdale, AZ, Feb. 15-16, 2019
We’d love to hear from you! Send your comments/questions to
And be sure to follow us on Twitter @AdamJBrownMD and